Nymox attributes increase in first-quarter net losses to higher clinical trial expenditures

Editorial Checklist Reviewed
Nymox Pharmaceutical CorporationMay 14 2010NewsGuard 100/100 Score

Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2010.

Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009. The increase in net losses is attributable to higher clinical trial expenditures compared to 2009. Product sales increased by 157% to $246,861 for the first quarter of 2010, compared to $96,226 for the same period in 2009. The weighted average number of common shares at March 31, 2010 was 31,473,825, compared to 30,253,246 at March 31, 2009.

Source:

Nymox Pharmaceutical Corporation

Posted in:

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Cognitive behavioral therapy shows promise for prolonged grief disorder
HEPA air purifiers fall short in cutting respiratory infections in aged-care facilities
Weight loss drug semaglutide may offer relief for knee arthritis pain
Ozempic effective for patients with chronic kidney damage
Matcha green tea enhances cognition and sleep in older adults
Vitamin K2 reduces the frequency, intensity, and duration of nighttime leg cramps
Telehealth mindfulness interventions significantly improve chronic pain outcomes for veterans
Higher diet quality associated with reduced risk of prostate cancer grade reclassification

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
AI outperforms doctors in diagnostics but falls short as a clinical assistant